文献速递类风湿关节炎其他结缔组织病

早期类风湿关节炎相关间质性肺病的危险因素及筛查策略外部验证

Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA.
PubMed 文献 · Lancet Rheumatol · 2025-10-14

SAIL-RA前瞻性队列的横断面分析纳入172例早期类风湿关节炎患者,11%经高分辨率CT确诊类风湿关节炎相关间质性肺病。中高疾病活动度(aOR 7.00)和年龄≥60岁(aOR 3.87)与间质性肺病强烈相关。多种筛查策略敏感性0.05至1.00、特异性0.11至0.97,需筛查人数3.6至7.7。

要点

  • 早期类风湿关节炎患者中11%存在类风湿关节炎相关间质性肺病。
  • 中高疾病活动度(aOR 7.00)与年龄≥60岁(aOR 3.87)与间质性肺病相关。
  • 多种筛查策略敏感性0.05至1.00、特异性0.11至0.97,需筛查人数3.6至7.7。

核心结论

  • 在早期类风湿关节炎人群中,11%患有类风湿关节炎相关间质性肺病。
  • 中高疾病活动度和年龄≥60岁与早期类风湿关节炎相关间质性肺病强烈相关。
  • 多种利用临床常规可获取因素的筛查策略显示出检测早期类风湿关节炎相关间质性肺病的潜力。

研究设计与样本

  • 对前瞻性SAIL-RA队列进行横断面分析,纳入2017年5月1日至2024年2月22日在美国五个学术医疗中心入组的172例完成高分辨率CT胸部成像的早期类风湿关节炎患者。
  • 早期类风湿关节炎定义为诊断后2年内;排除入组时妊娠或无法/不愿接受高分辨率CT胸部成像者。
  • 通过问卷调查、病史、高分辨率CT胸部成像、肺功能测试和自身抗体实验室检测进行评估,由胸部放射科医生独立审阅高分辨率CT识别类风湿关节炎相关间质性肺病。
  • 使用多变量逻辑回归分析危险因素,并报告多种筛查策略的预测性能。
  • 主要结局为类风湿关节炎相关间质性肺病的存在。

主要发现

  • 172例分析人群中128例(74%)为女性,44例(26%)为男性,平均年龄55.3岁(SD 13.7);171例中126例(74%)抗环瓜氨酸肽抗体阳性,170例中116例(68%)类风湿因子阳性;中位类风湿关节炎病程0.79年(IQR 0.36-1.60)。
  • 19例(11%)经高分辨率CT确诊类风湿关节炎相关间质性肺病。
  • 以28关节疾病活动评分联合红细胞沉降率≥3.2定义的中高疾病活动度与间质性肺病相关(aOR 7.00 [95%CI 1.95-25.13],对照为缓解或低疾病活动度)。
  • 年龄≥60岁与间质性肺病相关(aOR 3.87 [95%CI 1.33-11.27],对照为年龄<60岁)。
  • 筛查策略敏感性从Paulin标准(四点截断值)的0.05(95%CI 0.00-0.15)到ANCHOR-RA和ACR-CHEST标准(单因素截断值)的1.00(95%CI 0.97-1.00),特异性从ACR-CHEST标准(单因素截断值)的0.11(95%CI 0.06-0.16)到Paulin标准(四点截断值)的0.97(95%CI 0.95-1.0)。

关键数值与推荐

  • 中高疾病活动度(DAS28-ESR≥3.2)与间质性肺病相关aOR 7.00(95%CI 1.95-25.13),对照为缓解或低疾病活动度。
  • 年龄≥60岁与间质性肺病相关aOR 3.87(95%CI 1.33-11.27),对照为年龄<60岁。
  • ANCHOR-RA和ACR-CHEST标准(单因素截断值)敏感性均为1.00(95%CI 0.97-1.00)。
  • Paulin标准(四点截断值)敏感性0.05(95%CI 0.00-0.15),特异性0.97(95%CI 0.95-1.0)。
  • ACR-CHEST标准(单因素截断值)特异性0.11(95%CI 0.06-0.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evaluation of risk factors and screening strategies for rheumatoid arthritis-associated interstitial lung disease (ILD) in patients with early rheumatoid arthritis has been scarce. We investigated the prevalence of rheumatoid arthritis-associated ILD, risk factors, and the performance of proposed screening methods for rheumatoid arthritis-associated ILD in patients with early rheumatoid arthritis. METHODS: We performed a cross-sectional analysis of the prospective Study of Inflammatory Arthritis and Interstitial Lung Disease in Early RA (SAIL-RA). Study participants were eligible for inclusion if diagnosed with early rheumatoid arthritis, defined as being within 2 years of a diagnosis. Exclusions were pregnancy at enrolment or inability or unwillingness to obtain high-resolution CT (HRCT) chest imaging. Participants were enrolled at five academic health-care centres in the USA and assessed through surveys, medical history, HRCT chest imaging, pulmonary function tests, and laboratory testing for autoantibodies. Rheumatoid arthritis-associated ILD was identified through independent review of HRCTs by thoracic radiologists. We investigated risk factors for rheumatoid arthritis-associated ILD using multivariable logistic regression and reported the predictive performance of screening strategies for rheumatoid arthritis-associated ILD (from the ANCHOR-RA study; the 2023 guidelines from the American College of Rheumatology and American College of Chest Physicians [ACR-CHEST]; a four-factor risk score proposed in 2023; Sociedad Española de Reumatología and Sociedad Española de Neumología y Cirugía Torácica criteria; criteria proposed by Paulin and colleagues; and criteria derived from the ESPOIR cohort). The primary outcome was the presence of rheumatoid arthritis-associated ILD. FINDINGS: Participants were recruited between May 1, 2017, and Feb 22, 2024. Of 191 patients who were assessed for eligibility and included in the SAIL-RA cohort, 172 completed HRCT chest imaging and were included in this analysis: 128 (74%) were female, 44 (26%) were male, mean age was 55·3 years (SD 13·7), 126 (74%) of 171 were anti-cyclic citrullinated peptide (CCP) positive, 116 (68%) of 170 were rheumatoid factor positive, and median rheumatoid arthritis duration was 0·79 years (IQR 0·36-1·60); 19 (11%) had rheumatoid arthritis-associated ILD on HRCT. Factors associated with rheumatoid arthritis-associated ILD included moderate or high rheumatoid arthritis disease activity, determined by Disease Activity Score using 28 joints with erythrocyte sedimentation rate more than or equal to 3·2 (adjusted odds ratio [aOR] 7·00 [95% CI 1·95-25·13] vs remission or low disease activity) and age of 60 years or older (aOR 3·87 [1·33-11·27] vs age <60 years). Sensitivity of screening strategies ranged from 0·05 (95% CI 0·00-0·15) with the Paulin criteria (four-point cutoff) to 1·00 (0·97-1·00) with both the ANCHOR-RA and ACR-CHEST criteria (one-factor cutoff), and specificity ranged from 0·11 (0·06-0·16) with the ACR-CHEST criteria (one-factor cutoff) to 0·97 (0·95-1·0) with the Paulin criteria (four-point cutoff). The number of patients with early rheumatoid arthritis who needed to be screened to detect one case of rheumatoid arthritis-associated ILD ranged from 3·6 for the ESPOIR criteria (two-factor cutoff) to 7·7. INTERPRETATION: In this population with early rheumatoid arthritis, 11% had rheumatoid arthritis-associated ILD. Moderate or high disease activity and age of 60 years or older were strongly associated with rheumatoid arthritis-associated ILD in early rheumatoid arthritis. Several proposed screening strategies using factors routinely available at the point of care showed promise for detecting rheumatoid arthritis-associated ILD in early rheumatoid arthritis. FUNDING: National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Conditions, Rheumatology Research Foundation, University of Nebraska Medical Center, and University of Nebraska Health System.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. McDermott GC, Gill R, Byrne S, et al. Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA. Lancet Rheumatol. 2025. PMID: 41106411. doi:10.1016/S2665-9913(25)00158-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。